Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...